{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.26","value":"0.1"},{"groupId":"OG001","spread":"1.06","value":"-0.3"},{"groupId":"OG002","spread":"1.17","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"76"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.15","value":"-0.1"},{"groupId":"OG001","spread":"1.26","value":"-0.1"},{"groupId":"OG002","spread":"1.20","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"49"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.47","value":"0.03"},{"groupId":"OG001","spread":"1.19","value":"-0.1"},{"groupId":"OG002","spread":"1.31","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"35"}],"units":"Participants"}],"title":"Week 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"104"}],"units":"Participants"}],"description":"degrees celius","dispersionType":"Standard Deviation","groups":[{"description":"All grades of adverse events. Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined: 600 μg bid group includes all patients whose mean daily dose \\< 1500 μg /day.","id":"OG000","title":"600 µg Bid - All Grades"},{"description":"All grades of adverse events. Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined : 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day","id":"OG001","title":"900 μg - All Grades"},{"description":"All grades of adverse events for all patients who received 600 µg bid or 900 µg bid of pasireotide sub-cutaneous.","id":"OG002","title":"All Patients - All Grades"}],"paramType":"MEAN","populationDescription":"Number of patients with available data differed at visits","reportingStatus":"POSTED","timeFrame":"Baseline week 12, 24 and 48","title":"Percent Change in Cushing's Disease Clinical Signs and Symptoms - Temperature","type":"SECONDARY","unitOfMeasure":"percent change in celius"}